Pharma-Bio Serv

PBSV

Consulting Services · Industrials

Price

$0.54

+0.00 (+0.00%)

Market Cap

$12.4M

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Apr 30, 2026

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Dividends

Good

Track this stock — start free trial

Winston Score History

The full picture

Pharma-Bio Serv is a consulting and compliance services company that helps businesses in the pharmaceutical, biotechnology, food, and medical device industries follow government regulations. Its main services include training, audits, quality assurance support, and regulatory consulting. The company primarily serves manufacturers and producers who need to meet strict safety and quality standards set by agencies like the FDA.

The company earns revenue by charging fees for its consulting projects and training programs rather than selling physical products. It operates mainly in Puerto Rico and the broader United States, serving a region with a significant concentration of pharmaceutical manufacturing facilities. Pharma-Bio Serv is a small company with a market cap near zero, and it faces real financial pressure, as its negative operating margin shows it is currently spending more than it earns. The key risk is its small size and limited resources, which make it vulnerable to losing clients to larger, better-funded consulting firms.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+11.8% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+142.9% YoY

YoY Growth Rate

Strong earnings growth

R&D Spend

$0/ year

0.0% of revenue

Below sector average (4%)

Research and development spending

Insider Activity

64.7%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

$8M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Pharma-Bio Serv has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

−0.3% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 23.0M (2021) → 23.0M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

33.4%

Modest — 33.4% gross margin

Profit after running costs

Operating Margin

5.4%

Thin — 5.4% operating margin

Return on the money invested

ROCE

-0.0%

Weak — -0.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-5.5%

Shrinking sales (-5.5% YoY)

Profit growth

EPS YoY

-192.9%

Earnings shrinking (-192.9% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

-593855%

Weak — only -593855% of profit becomes cash

Spare cash per sale

FCF Margin

-4008.4%

Burning cash (-4008.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

13.89%

Healthy income — 13.89% yield

Yield above 6% — often a flag the market is pricing in a cut.

Dividend record

Dividend Growth

+0.0%

Dividend flat

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial